The company's suite of therapeutic platforms and fully integrated drug development engine enable precise engineering of differentiated product candidates, including zanidatamab, a HER2-targeted bispecific antibody being evaluated in multiple clinical trials globally, and Zanidatamab Zovodotin, a bispecific antibody-drug conjugate currently in Phase 1 clinical development. Zymeworks is also advancing a deep preclinical pipeline in oncology and other therapeutic areas and has strategic partnerships with nine biopharmaceutical companies.